CURRENT
ISSUE
1643

The FDA has approved Vuity (Abbvie), a 1.25% ophthalmic solution of the muscarinic receptor agonist pilocarpine hydrochloride, for treatment of presbyopia in adults. Pilocarpine 1%, 2%, and 4% ophthalmic solutions (Isopto Carpine, and others) have been available for years for treatment of glaucoma, but local and systemic adverse effects have limited their use.1

STANDARD TREATMENT — Presbyopia is an age-related condition thought to be caused by weakening of ciliary muscles or loss of lens elasticity. Corrective lenses, including single-vision, bifocal, trifocal, or progressive lenses and single-vision or multifocal contact lenses...  Continue reading

More from Issue 1643
Previous Issue: 1642      January 24, 2022
Coming Soon
Tezepelumab (Tezspire) for Severe Asthma
Remimazolam (Byfavo) for Short-Term Sedation
Cabotegravir (Apretude) for Pre-Exposure Prophylaxis of HIV-1 Infection
Search
Donate
Subscribe
Conversation
Follow us   Twitter LinkedIn YouTube Blog RSS   Email Alerts
FROM
ISSUE
1643

Difelikefalin (Korsuva – Vifor), an IV kappa opioid receptor (KOR) agonist, has been approved by the FDA for treatment of moderate to severe pruritus associated with chronic kidney disease (CKD) in adults on hemodialysis. It is the first drug to be approved for this indication and the first KOR agonist to become available in the US. Difelikefalin has not been studied in patients on peritoneal dialysis.

THE DISORDER — CKD-associated pruritus is common in patients on hemodialysis. Repetitive scratching can lead to ... Continue reading

 Tweets